Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Macy's CEO Tony Spring, who is trying to turn around the company, wants to prove to the public markets that its three-brand ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...

"For patients in high-deductible health plans or who have cost sharing arrangements the increases will hit them." Find out if ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV prevention medicine, impact of the incoming Trump administration on health care, and ...

San Francisco and its hotel industry are partnering to beef up security around this week's 43rd annual J.P. Morgan Healthcare ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $89.88 which represents a slight increase of $0.74 or 0.83% from the prior close of $89.14. The stock opened at $90.19 and ...

Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...